HARMONY OUTCOMES

HARMONY OUTCOMES is the trial with the most awkward timing in the GLP-1 story. It enrolled 9,463 adults with type 2 diabetes and established cardiovascular disease, randomizing them to albiglutide or placebo. Hernandez and colleagues published it in The Lancet in 2018, and the result was clearly positive.

The primary composite of cardiovascular death, heart attack and stroke occurred in 338 of 4,731 participants (7%) on albiglutide versus 428 of 4,732 (9%) on placebo — 4.6 versus 5.9 events per 100 person-years, a hazard ratio of 0.78. Albiglutide was superior to placebo, not merely noninferior, over a median of just 1.6 years. That is a large effect appearing quickly.

The problem is that by publication day, the drug was gone. GSK had already withdrawn albiglutide (marketed as Tanzeum) from global markets in 2017, citing limited commercial uptake rather than any safety concern. The trial was allowed to run to completion and report, but no patient could act on the result.

This is the most useful thing the trial teaches, and it is not about cardiology. Drug availability is decided by commercial performance, not by evidence quality. AMPLITUDE-O told the same story three years later with efpeglenatide: a superiority result for a medicine nobody can fill. When you read a striking trial finding, the first question worth asking is whether the drug is on a pharmacy shelf near you.

The clinical takeaway is narrower but real: the finding supports the idea that cardiovascular benefit is achievable across structurally different long-acting GLP-1 molecules, which strengthens the case for the ones that remain. Worth asking your clinician: which GLP-1 with cardiovascular evidence is both appropriate for you and actually available. Our HARMONY OUTCOMES deep dive, albiglutide entry and cardiovascular study roundup cover the rest of the field.